Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smyth, J. E
Right arrow Articles by Leonard, R. C. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, J. E
Right arrow Articles by Leonard, R. C. F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 2:755-758, 1991
© 1991 European Society for Medical Oncology

research-article

Original article: Cisplatinum and prednimustine, an active regimen for advanced epithelial ovarian cancer

J. E Smyth1,, G. J. Beattie1, M. E. Stewart1, V J. Cowie1, G. E. Smart2, J. R. B. Livingstone2 and R. C. F Leonard1

1University Department of Clinical Oncology, Western General Hospital Edinburgh, UK
2Department of Obstetrics and Gynaecology, Royal Infirmary Edinburgh, UK

Correspondence to: Professor J. F. Smyth, University Department of Clinical Oncology, Western General Hospital, Crewe Road, Edinburgh. EH4 2XU, UK

80 patients with advanced epithelial ovarian carcinoma were treated for 6 months with cisplatinum and prednimustine following initial surgery. Response to treatment was assessed by second-look surgery. The objective response rate was 69% with 38% achieving a complete response for up to 55 months. The toxicity of this regimen was acceptable. Statistically, de-bulking or partial de-bulking had a significant beneficial effect on the likelihood of a complete response. The best survival figures were associated with maximum de-bulking. The combination of cisplatinum and prednimustine is a new and active regimen for operable advanced epithelial ovarian carcinoma.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.